Integration of PSMA PET into the New Recommendations from Prostate Cancer Working Group 4 for Prostate Cancer Trials

Area of Science:

• Oncology
• Radiology
• Clinical Trials

Background:

• Prostate Cancer Working Group 4 (PCWG4) guidelines update previous frameworks for evaluating prostate cancer progression and treatment.
• Advances in imaging, particularly prostate-specific membrane antigen (PSMA) PET, necessitate revised guidelines.

Purpose of the Study:

• To summarize the updates and rationales within the PCWG4 guidelines.
• To highlight the integration of PSMA PET and new terminology in clinical trial frameworks.

Main Methods:

• Review of the PCWG4 guidelines, focusing on changes from PCWG3.
• Analysis of the incorporation of PSMA PET and updated response criteria.
• Examination of new terminology for disease classification.

Main Results:

• PCWG4 replaces "castration-sensitive" and "castration-resistant" with androgen pathway modulation classifications.
• PSMA PET is integrated throughout the disease continuum for staging, recurrence, and response assessment.
• Conventional imaging remains validated, but PSMA PET is increasingly used in clinical trials.

Conclusions:

• PCWG4 improves disease characterization and biomarker-driven therapeutic evaluation in prostate cancer trials.
• Standardized evaluation and data collection support PSMA PET validation as a clinical trial endpoint.
• These updates pave the way for future advancements in prostate cancer research methodology.